HC Wainwright Issues Pessimistic Outlook for DAWN Earnings

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) – Analysts at HC Wainwright decreased their Q2 2025 earnings per share estimates for shares of Day One Biopharmaceuticals in a report issued on Wednesday, May 7th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of ($0.32) per share for the quarter, down from their prior forecast of ($0.30). HC Wainwright has a “Buy” rating and a $36.00 price objective on the stock. The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Day One Biopharmaceuticals’ Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.25) EPS, FY2026 earnings at ($0.34) EPS and FY2027 earnings at $0.58 EPS.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its earnings results on Tuesday, May 6th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.11. The company had revenue of $30.76 million for the quarter, compared to the consensus estimate of $30.28 million.

DAWN has been the topic of a number of other reports. The Goldman Sachs Group cut their price target on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating on the stock in a report on Tuesday, March 25th. Wedbush reaffirmed an “outperform” rating and set a $25.00 price objective on shares of Day One Biopharmaceuticals in a research report on Wednesday. Needham & Company LLC reduced their price target on Day One Biopharmaceuticals from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating for the company in a research report on Wednesday, March 5th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Day One Biopharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $30.57.

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ DAWN opened at $6.45 on Friday. Day One Biopharmaceuticals has a 1 year low of $6.26 and a 1 year high of $17.14. The company has a market cap of $653.78 million, a P/E ratio of -6.26 and a beta of -1.24. The firm has a 50-day simple moving average of $7.70 and a two-hundred day simple moving average of $11.08.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. acquired a new stake in shares of Day One Biopharmaceuticals during the 4th quarter valued at about $27,000. R Squared Ltd purchased a new position in Day One Biopharmaceuticals during the fourth quarter worth approximately $31,000. Tower Research Capital LLC TRC grew its holdings in Day One Biopharmaceuticals by 911.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 10,657 shares of the company’s stock valued at $135,000 after purchasing an additional 9,603 shares during the period. Pallas Capital Advisors LLC purchased a new stake in shares of Day One Biopharmaceuticals in the first quarter valued at approximately $87,000. Finally, Wealth Enhancement Advisory Services LLC acquired a new position in shares of Day One Biopharmaceuticals during the 1st quarter worth approximately $88,000. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Insider Activity

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 12,048 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $144,094.08. Following the completion of the transaction, the chief executive officer now directly owns 128,015 shares of the company’s stock, valued at approximately $1,531,059.40. The trade was a 8.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, General Counsel Adam Dubow sold 4,646 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $55,566.16. Following the sale, the general counsel now directly owns 39,602 shares in the company, valued at $473,639.92. The trade was a 10.50 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 21,064 shares of company stock valued at $251,925 in the last quarter. 6.20% of the stock is currently owned by company insiders.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.